Cisplatin and Oncolytic Adenoviral Vector Co-Treatment Induces Synergistic Proliferation Inhibitory Effects in Breast Cancer Cells

Muhammad Tahir; Abdul Rehman; Adeel Riaz

Authors

Muhammad Tahir College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, P.R China
Abdul Rehman Department of Biochemistry, PMAS Arid Agriculture University, Rawalpindi 46000, Pakistan
Adeel Riaz Department of Biochemistry, PMAS Arid Agriculture University, Rawalpindi 46000, Pakistan.

Keywords:

Adenoviral Vectors, Apoptosis, Cisplatin, Breast Cancer, p53, Cell cycle

Abstract

Objective: To investigate the proliferation inhibitory effects of Cisplatin, CRAd mono, or Cis-CRAd combined therapy in MCF-10 breast cancer cells.

Methodology: In this prospective cohort study tumor inhibition activity of cisplatin, CRAd alone, and in combination, was studied. Breast cancer cells MCF-10 (ATCC, CRL-10317) were obtained from ATCC. These were cultured and propagated following the standard procedures.Cell viability assay and flow cytometry-based assay were used to measure the tumor cell growth inhibition, apoptosis induction, and cell cycle arresting ability of both anti-cancer agents in breast tumor cells. Further, the mRNA expression of p53 and its downstream target genes responsible for apoptosis induction and cell cycle arrest measured by RT-qPCR.

Results: Combined therapy with Cisplatin-CRAd significantly inhibited the cell growth, induced apoptosis, and blocked G2-M phase cell cycle transition in breast cancer cells. The mRNA expression analysis of p53 and its downstream genes responsible for apoptosis induction and cell cycle arrest was found out to be elevated in treated breast tumor cells.

Conclusion: Cisplatin, if used in combination with other competent and non-toxic anti-cancer agents like CRAd, can produce better anti-cancer effects at low doses. The results of this study indicate such a combined treatment approach may be investigated in animal models then at the clinical level.